A woman living in northwestern Washington has died from measles, according to state health officials, NBC News reports.» Read More
Drug pricing pressure under a Democratic administration be darned. $75,000. That's not a salary figure. That's the price one biotech analyst says Vertex Pharmaceuticals and its partner Johnson & Johnson might be able to charge--possibly even more--for their Hepatitis C drug.
For months now several analysts have been pointing out that despite big pharma's many problems some of the companies still pay healthy dividends. And when T-bills are offering next to nothing, a solid dividend yield in these rough and tumble times is a good thing.
CEOs of big drug companies are rarely, if ever, publicly candid about the price of their stock. You usually get the boilerplate line about how they manage the business and the market will do whatever.
Analysts have a one-day respite between two major pharma R & D days and they're using it to size up Merck's update yesterday and to set expectations for Eli Lilly's briefing tomorrow.
I wrote this morning's post from the Merck analyst meeting before sitting down for my exclusive interview with Exec Veep Ken Frazier. So, I had to pass along this fresh anecdote that illustrates even more how far this drug company and its people have come.
Sitting here at Merck's annual drug research and development for the Street in the media room at the company's headquarters in central New Jersey. This year, for the first time, MRK is allowing reporters into the actual meeting room with the 300 or so analysts and investors
Earlier this week UBS pharmaceutical analyst Roopesh Patel put out a big 2009 sector outlook research note claiming, "So far, the global economic slowdown has had no noticeable impact — a) U.S. weekly and monthly U.S. prescription trends are stable; b) there also is no meaningfully cautionary commentary from any of the companies...." Well, he might have spoken too soon.
Look for M&A activity—big and small—a pair of breakthrough drugs and the prospect of government price controls.
Does the Food and Drug Administration approve drugs anymore? Or are we seeing the lame-duck leadership at the agency punt any action over to the next administration?
As the market remains focused on Citi and the President-elect's midday cabinet announcement there are a few newsworthy things going on in biopharmaland.
Over the course of his congressional career the CRP shows that not a single drug company ever broke onto Daschle's top-20 list of contributors. The only healthcare-related firm that pops up is Invacare.
Wall Street has essentially thrown in the towel lately on Amylin Pharmaceuticals. The shares have plummeted from nearly $30 just three months ago to around $7 today.
How in the world is Merck gonna rebrand a product it has spent so much time, effort and money gearing toward females so that males will use it, too? I'm not sure, but it'll be interesting to watch if or when MRK wins Food and Drug Administration approval of Gardasil for boys/young men.
Big pharma's got big problems. That should not come as news to anyone who works for, follows or invests in the industry.
While on the elliptical at the gym the other night I was watching one network newscast and the person on the machine next to me was watching another one.
Even before the results of the election were official there was already speculation in the blogosphere about who might become the next Commissioner of the Food and Drug Administration under a President Obama.
I’m sure you’ve seen all the stories regarding athletes and staph infections more technically known as MRSA. Although the information each time has been sketchy, the names Kellen Winslow, Tom Brady and Peyton Manning have become associated with it in recent weeks.
You gotta feel sorry for the folks at Merck. Immediately after the drugmaker finishes a program to get rid of more than 10,000 employees, the company drops the ax again.
As we head into the weekend (TGIF, right?), I wanted to clean out the ol' inbox.
I don't think Eli Lilly will be running any more "Coming Soon" ads--like the one posted here for its late-stage experimental bloodthinner Effient--for drugs that haven't been approved yet by the Food and Drug Administration.